IGF-1 LR3
≥99% HPLC verified · 1 size available
Synthetic IGF-1 analog with reduced binding-protein affinity, studied in growth-pathway research.
What research has shown
Synthetic compound
Defined synthetic material for controlled laboratory research and analytical method development.
In the literature
Cited across published research on peptide stability, receptor interaction, and biological signaling.
Lab settings
Examined in vitro and in preclinical models. Studies focus on molecular properties under controlled systems.
Non-therapeutic
For laboratory research only. Not approved for human consumption, treatment, or therapeutic application.
About this compound
IGF-1 LR3 is a synthetic analog of insulin-like growth factor 1 (IGF-1) with two structural modifications: an arginine substitution at position 3 and an extended N-terminal sequence. These modifications reduce binding affinity for IGF binding proteins (IGFBPs), increasing the proportion of free IGF-1 available for receptor interaction. The compound is referenced in research literature on IGF-receptor pathway signaling and growth pathway research models.
Each Perplexa lot is independently HPLC-verified at ≥99% purity with identity confirmed by mass spectrometry.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
This material is supplied for in vitro research only. It is not a drug, supplement, food, or cosmetic, and is not for human or veterinary consumption.
Specifications
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC) |
| Size | 1MG |
| Vial | 3ML |
| Storage | -20°C, desiccated, protected from light |
| Origin | USA |
| Solubility | Requires acidic diluent (e.g., 0.6% acetic acid). Standard bacteriostatic water is NOT appropriate. |
| Mol. Weight | 9111.04 g/mol |
Reconstitution, storage, and handling are the responsibility of the qualified researcher.Perplexa Labs does not provide protocols, dosing guidance, or human-use instructions.